Game Changer: Hepatitis C Drug May Revolutionize Treatment

Bruce Bacon, M.DThe drug boceprevir helps cure hard-to-treat hepatitis C, says Saint Louis University investigator Bruce R.Bacon, author of the March 31 New England Journal of Medicine article detailing the study's findings. The results, which were first reported at the 61st annual meeting of patients who have not responded to standard treatment.

Bacon, who is professor of internal medicine at Saint Louis University School of Medicine and co-principle investigator of the HCV RESPOND-2 study, studied the protease inhibitor boceprevir and found that it significantly increased the number of patients whose blood had undetectable levels of the virus.

'These findings are especially significant for patients who don't respond to initial treatment,' said Bacon. 'When the hepatitis C virus is not eliminated, debilitating fatigue and more serious problems can follow'.

To view full article CLICK HERE